×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)

F-star Therapeutics (NASDAQ:FSTX) Downgraded by SVB Leerink to Market Perform

Thursday, June 23, 2022 | MarketBeat

F-star Therapeutics (NASDAQ:FSTX - Get Rating) was downgraded by equities researchers at SVB Leerink from an "outperform" rating to a "market perform" rating in a research note issued to investors on Thursday, The Fly reports.

FSTX has been the subject of a number of other reports. HC Wainwright initiated coverage on F-star Therapeutics in a research note on Tuesday, May 17th. They set a "buy" rating and a $35.00 price objective for the company. LADENBURG THALM/SH SH cut F-star Therapeutics from a "buy" rating to a "neutral" rating in a research note on Thursday. Laidlaw cut F-star Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday. Finally, William Blair cut F-star Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Thursday. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $29.50.

Shares of FSTX stock traded up $0.03 on Thursday, reaching $6.39. 1,220,888 shares of the stock were exchanged, compared to its average volume of 207,453. F-star Therapeutics has a one year low of $2.07 and a one year high of $9.30. The company has a current ratio of 6.11, a quick ratio of 6.11 and a debt-to-equity ratio of 0.14. The stock has a 50 day moving average price of $3.04 and a 200 day moving average price of $3.64.


F-star Therapeutics (NASDAQ:FSTX - Get Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.57) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.06. The company had revenue of $2.55 million for the quarter, compared to analyst estimates of $2.30 million. As a group, equities research analysts expect that F-star Therapeutics will post -2.35 EPS for the current year.

Large investors have recently bought and sold shares of the business. Envestnet Asset Management Inc. acquired a new position in F-star Therapeutics in the first quarter valued at about $48,000. JPMorgan Chase & Co. boosted its position in shares of F-star Therapeutics by 152.7% during the first quarter. JPMorgan Chase & Co. now owns 21,335 shares of the company's stock worth $76,000 after buying an additional 12,891 shares during the period. Goldman Sachs Group Inc. acquired a new position in shares of F-star Therapeutics during the first quarter worth about $120,000. State Street Corp grew its holdings in shares of F-star Therapeutics by 15.6% during the first quarter. State Street Corp now owns 53,150 shares of the company's stock worth $189,000 after buying an additional 7,180 shares in the last quarter. Finally, BlackRock Inc. raised its position in F-star Therapeutics by 1.6% in the 1st quarter. BlackRock Inc. now owns 295,947 shares of the company's stock valued at $1,050,000 after buying an additional 4,776 shares during the last quarter. 51.67% of the stock is owned by hedge funds and other institutional investors.

About F-star Therapeutics (Get Rating)

F-star Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients.

Further Reading

The Fly logo

Analyst Recommendations for F-star Therapeutics (NASDAQ:FSTX)

Should you invest $1,000 in F-star Therapeutics right now?

Before you consider F-star Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and F-star Therapeutics wasn't on the list.

While F-star Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:


Most Read This Week

Recent Articles

Search Headlines:

Latest PodcastHow To Navigate The Market Downturn Like A Pro

In this episode, Kate sits down with Kyrill Astur, CEO of portfolio management firm Centerfin. Kyrill brings a background from Wall Street and hedge funds to his current role helping individual investors navigate the market challenges while investing for their future.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.